| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
We have reported the effectiveness of transplanting human iPS cell-derived Neural Stem/Progenitor Cells (hiPS-NS/PCs) for spinal cord injury in rodents as well as primates. Although hiPSC derivatives are considered promising cellular resources for regenerative medicine, their tumorigenicity potentially limits their clinical application. Improved cell quality and safety will be crucially important for any clinical use of hiPSC-NS/PCs. To gain insight into the mechanisms underlying the regulation of tumorigenicity in hiPSC-NS/PCs, we performed a series of integrated DNA methylation and gene expression analyses using tumorigenic and non-tumorigenic hiPSC-NS/PCs. These results indicate that different NS/PC clones have different DNA methylomes and that DNA methylation patterns are unstable as cells are passaged. Therefore, DNA methylation profiles should be included in the criteria used to evaluate the tumorigenicity of hiPSC-NS/PCs in the clinical setting.
|
